Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

Notable signs and symptoms distinguishing bronchiectasis from other pulmonary disease states are discussed. This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on the ...

Please provide your email address to receive an email when new articles are posted on . New endpoints from the ASPEN trial were presented at the World Bronchiectasis Conference. FDA new drug ...

Please provide your email address to receive an email when new articles are posted on . For adults with bronchiectasis, $82,545 was the highest annual health care cost observed in a systematic review.

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the ...

Manage bronchiectasis effectively with these practical lifestyle tips that can help reduce flare-ups, prevent infections, and keep your lungs clear.

FIRS organizations, including the American Thoracic Society, call for improving early detection of bronchiectasis. July 1, 2025 – According to the 2022 Global Impact of Respiratory Disease Report, the ...

This chronic lung condition causes your airways to become permanently widened and scarred. Learn how to spot and treat this ...

CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.